Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business IPO filing

Iambic Therapeutics Files for US IPO

Analysis based on 8 articles · First reported Sep 21, 2026 · Last updated Sep 22, 2026

Sentiment
10
Attention
2
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The listing expands the biotech IPO pipeline and signals continued investor appetite for AI-driven drug discovery, supporting valuations across the sector. Underwriting banks and Nasdaq stand to gain fees and listing revenue, while the broader IPO market remains pressured by the Iran war, rising bond yields and rate hikes.

biotechnology pharmaceuticals investment banking

Iambic Therapeutics, a San Diego-based drug developer backed by Nvidia and the Qatar Investment Authority, filed for a US initial public offering on Monday, September 21, 2026, aiming to list on the Nasdaq under the symbol IAM. The company, founded in 2019 as Entos, is advancing a pipeline of AI-discovered drug candidates for solid tumors, with its most advanced candidate IAM1363 in an early-stage trial for solid tumors such as breast cancer. Earlier the same day, Iambic and AbbVie unveiled a multi-year collaboration to accelerate AI-driven discovery of small molecule therapies. Iambic has raised roughly $461.8 million since inception from technology- and healthcare-focused investors, counting Catalio Capital Management, Nexus Ventures and Coatue Management among its major backers. JPMorgan Chase, Jefferies, Bank of America and Citigroup are the underwriters. The filing adds to a busy fall biotech IPO slate that also includes Retension Pharmaceuticals and TRex Bio, which filed on Friday, and ADARx Pharmaceuticals, which launched its roadshow earlier on Monday. Analysts note biotech listings have remained relatively insulated from broader IPO market pressures tied to the Iran war, AI-led disruptions, rising bond yields and interest rate hikes, with all five of the year's best-performing IPOs of $50 million or more being biotechs, according to Renaissance Capital strategist Matt Kennedy.

95 Iambic Therapeutics filed for IPO
70 Iambic Therapeutics unveiled collaboration AbbVie
30 Retension Pharmaceuticals filed for listing
30 TRex Bio filed for listing
25 ADARx Pharmaceuticals launched roadshow
priv
The central entity of the event, filing for a US IPO on Nasdaq under symbol IAM and unveiling an AI drug discovery collaboration with AbbVie. A successful listing would give it fresh capital and public-market valuation.
Importance 100.0 Sentiment 30.0
stock
Entered a multi-year collaboration with Iambic to accelerate AI-driven discovery of small molecule therapies, expanding its early-stage pipeline.
Importance 45.0 Sentiment 10.0
stock
A major backer of Iambic, gaining a potential public-market exit and reinforcing its AI healthcare investment footprint.
Importance 40.0 Sentiment 10.0
priv
Sovereign wealth fund backer of Iambic, positioned to realize gains from the IPO.
Importance 35.0 Sentiment 10.0
stock
Serving as an underwriter for the Iambic IPO, earning fees from the offering.
Importance 25.0 Sentiment 5.0
priv
Serving as an underwriter for the Iambic IPO, earning fees from the offering.
Importance 25.0 Sentiment 5.0
stock
Serving as an underwriter for the Iambic IPO, earning fees from the offering.
Importance 25.0 Sentiment 5.0
stock
Serving as an underwriter for the Iambic IPO, earning fees from the offering.
Importance 25.0 Sentiment 5.0
exch
The exchange where Iambic aims to list under the symbol IAM, gaining a new listing.
Importance 20.0 Sentiment 5.0
priv
A major backer of Iambic, positioned to benefit from the IPO.
Importance 15.0 Sentiment 5.0
priv
A major backer of Iambic, positioned to benefit from the IPO.
Importance 15.0 Sentiment 5.0
priv
A major backer of Iambic, positioned to benefit from the IPO.
Importance 15.0 Sentiment 5.0
priv
Its strategist Matt Kennedy provided commentary on the biotech IPO strength, framing the sector's resilience.
Importance 15.0 Sentiment 5.0
priv
Launched its IPO roadshow the same day, part of the busy fall biotech listing slate.
Importance 15.0 Sentiment 5.0
priv
Filed for a US IPO on Friday, adding to the biotech listing wave.
Importance 15.0 Sentiment 5.0
+ 7 more entities View on Dashboard
Nvidia related ↔ JPMorgan Chase
Nvidia related ↔ Jefferies
Nvidia related ↔ Bank of America
Nvidia related ↔ Citigroup
Nvidia related ↔ Nasdaq
JPMorgan Chase related ↔ Nasdaq
Jefferies related ↔ Nasdaq
Bank of America related ↔ Nasdaq
Citigroup related ↔ Nasdaq
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.